ANZCTR search results

The aim of this randomised controlled trial is to develop, implement and evaluate a community-based intervention to promote physical activity among adults diagnosed with Type 2 Diabetes, at high risk of Type 2 Diabetes or overweight /obese. The 20-week intervention will include five sessions with a qualified personal trainer and a smartphone App. Aerobic fitness, muscular strength, physical activity, functional mobility, BMI, waist circumference, blood pressure, and cognitive variables will be assessed. Assessment will be conducted at baseline, 10-weeks and 20-weeks.

This study aims to determine whether acupressure therapy will be able to improve sleep quality in patients receiving haemodialysis (HD) or haemodiafiltration (HDF) for treatment of end stage kidney disease (ESKD). Other outcomes include change in quality of life, adverse reaction at the site of acupressure application and patient acceptability.

The ingestion of excess energy, particularly fat, is largely responsible for the current epidemic of lifestyle-related diseases such as obesity, diabetes and sarcopenia (the progressive loss of muscle mass with increasing age). The development of sarcopenia is exacerbated by low levels of physical activity and also in overweight or obese individuals through an increase in body fat and concomitant decrease in muscle mass. However, performing resistance and aerobic exercise in combination with the ingestion of high-quality protein sources (e.g., dairy-based protein) has been shown to enhance and/or maintain muscle mass. This has important health implications for reducing the risk of developing sarcopenia, obesity or other debilitating health conditions such as diabetes. Accordingly, the aim of this research is to investigate whether high fat levels decreases the muscle growth response following resistance and endurance exercise and protein ingestion.

The purpose of this study is to assess if the drug, PAX-1, can reduce cancer pain when used in addition to usual pain medication. It will also assess the side effects it may cause. Who is it for? You may be eligible to join this study if you are aged 18 years or above and are experiencing moderate or severe, persistent cancer-related pain are in the palliative setting. Study details: Participants in this study will be randomly (by chance) allocated to one of four groups. Participants in three of the groups will receive the study drug, PAX-1, at a dose of either 7.5mg, 10mg, or 12.5mg . Participants in the fourth group will receive a placebo (inactive) tablet. The tablets are taken orally 3 times a day for 28 days. All participants will continue to take their usual pain medication in addition to the study medication. They will not know to which group they have been allocated until after the study. Participants will be asked to record their daily pain intensity on a numerical rating scale. They will also be asked to complete questionnaires on appetite, sleep quality, functional status, and quality of life and will undergo safety and tolerability evaluations involving blood tests, ECGs and monitoring of adverse events. This will enable us to determine the clinical benefit of PAX-1 for cancer patients in the palliative setting.

Fixed airway narrowing is a common complication of long standing asthma. It occurs despite good treatment with puffers that are effective in controlling inflammation. It causes symptoms such as wheeze, cough, shortness of breath and there is no known treatment for asthma related fixed airway narrowing because the mechanisms and causes are poorly understood. It is more common in older patients who have had asthma for many years, in whom there are also greater symptoms. Airway inflammation due to neutrophils is more common in older people with asthma who have fixed airway narrowing. Neutrophils are a type of cell that are part of the body's immune system which causes inflammation. Neutrophilic airway inflammation can cause damage to the airways and lung tissue. The aim of this research is to determine how neutrophils affect the function of the smaller airways in older people with asthma. We will also determine how neutrophils cause airway and lung damage, which can lead to fixed airway narrowing. We will recruit people with asthma who are >40 years of age, are non smokers and have no other significant lung or heart problems. Participants will undergo breathing tests and a bronchoscopy, using a small camera on the end of a flexible tube, to obtain samples from their lungs. The significance of this study will be the discovery of the mechanisms that underlies this major complication of asthma. It will assist in overcoming the major barrier halting progress to an effective treatment strategy for which the mechanisms are unknown.

This study is designed to assess the safety, tolerability and pharmacokinetic profile of orally inhaled PB01 when administered to healthy male volunteers (aged between 18 and 55 years) as a single dose (Stage 1 component of the study) and 14 consecutive once daily doses (Stage 2 component of the study) at dose levels up to 30 mg. Stages 1 and 2 will be conducted in Australia.

It has been suggested that faulty biomechanics contribute to the high rate of lower extremity injuries in basketball and netball. This project will involve a cluster randomized controlled trial that will investigate if a sports-specific injury prevention program results in changes in landing biomechanics among netball and basketball players.

This will be a placebo randomised control trial conducted in the neonatal intensive care unit. The trial will compare oral paracetamol against current standard therapy for a haemodynamically significant ductus arteriosus, which is intravenous indomethacin.

Androgenetic Alopecia (AGA) which is also known as male patern baldness is a common form of hair loss in both men and women. Samumed Company is developing SM04554 for the treatment of AGA. SM04554 is a small molecule which activates proteins involved in maintaining hair growth The purpose of this study is to learn more about the safety and activity of a SM04554. This study drug is a solution to be rubbed onto the scalp once every day for 14 days. To obtain information on the how the body absorbs distributes and removes the drug form the body (pharmacokinetics), blood samples will be taken to measure the concentration of the study drug over the 14 days of application. This study will also check safety by measuring heart, liver and kidney function, number of blood cells, vital signs and scalp assessments.

This project will evaluate the Training in Interaction, Communication and Literacy (TICL) program through a cluster randomised trial. TICL is a 10 week professional development program for Early Childhood Educators (ECEs), delivered by Speech Pathologists, and designed to improve the language and early literacy skills of preschoolers. Pre and post measures of changes in the knowledge and skills of ECEs and the language and literacy skills of the preschoolers they care for will be taken. These results will be compared with a control group of ECEs and preschoolers. We hypothesise that TICL will improve the language and early literacy skills of preschoolers when compared with no treatment.